Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-130277 vs Subcutaneous Apomorphine in PD Motor Fluctuations
NCT03391882Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of apomorphine in Parkinson's disease (PD), sponsored by Sumitomo Pharma America. Started Dec 2018; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03391882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03391882.